fludarabine has been researched along with Hematologic Neoplasms in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (3.15) | 18.2507 |
| 2000's | 104 (46.85) | 29.6817 |
| 2010's | 100 (45.05) | 24.3611 |
| 2020's | 11 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, JM; Anderson, MA; Blombery, P; Carney, DA; Chen, X; Dengler, MA; Handunnetti, SM; Huang, DCS; Lew, TE; Lin, VS; Nguyen, T; Panigrahi, A; Roberts, AW; Seymour, JF; Tam, CS; Thompson, ER; Wei, AH; Westerman, DA | 1 |
| Ali, N; Bal, SK; Boughan, KM; Caimi, PF; Cooper, BW; de Lima, M; de Rezende, ACP; Gallogly, M; Hamerschlak, N; Kerbauy, L; Kerbauy, MN; Latif, BM; Malek, E; Mansur, D; Metheny, L; Otegbeye, F; Pereira, G; Ribeiro, AF; Sakuraba, R; Sanchez, G; Sekaly, RP; Sharma, AA; Tomlinson, BK; Weltman, E | 1 |
| Artz, AS; Aydogan, B; Bishop, MR; Hasan, Y; Kline, J; Kosuri, S; LaBelle, JL; Larson, RA; Liu, H; Partouche, J; Riedell, PA; Stock, W; Tran, MC; Wang, A; Weichselbaum, R; Yenice, K | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
| Brinda, BJ; Foxworthy Scott, S; Karr, AH; Kiel, PJ; Nelson, RP; Podichetty, JT; Prasad, NK; Quinney, S | 1 |
| Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J | 1 |
| Boelens, JJ; de Witte, MA; Dorlo, TPC; Huitema, ADR; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM | 1 |
| Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T | 1 |
| Ashida, T; Atsuta, Y; Fukuda, T; Hara, M; Ichinohe, T; Ikeda, T; Ishikawa, T; Kawakita, T; Maruyama, Y; Morishige, S; Shimomura, Y; Takada, S; Takanashi, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| Isobe, M; Konuma, T; Monna-Oiwa, M; Okabe, M; Takahashi, S; Tojo, A | 1 |
| Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S | 1 |
| Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM | 1 |
| Alousi, A; Burke, E; Cao, K; Champlin, R; Chen, J; de Lima, M; Hosing, C; Kaur, I; Kebriaei, P; Marin, D; Mehta, RS; Olson, A; Oran, B; Parmar, S; Popat, U; Rezvani, K; Saliba, RM; Shah, N; Shpall, EJ; Skerrett, D | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Calip, G; Oh, A; Patel, P; Rondelli, D; Sweiss, K | 1 |
| Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Jones, R; Kawedia, J; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Nieto, Y; Olson, A; Oran, B; Parmar, S; Popat, UR; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Srour, SA; Valdez, BC | 1 |
| Calip, GS; Oh, AL; Patel, PR; Rondelli, D; Sweiss, K | 1 |
| Stanford, M; Virgo, J; Williams, G | 1 |
| Hatsumi, N; Hoshino, T; Sakura, T; Takada, S | 1 |
| Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A | 1 |
| Artz, A; Bishop, MR; Champlin, RE; Chen, J; Ciurea, SO; Gergis, U; Guarneri, D; Liu, H; Mayer, SA; Rondon, G; Shore, T; Srour, SA; Stock, W; van Besien, K | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, M; Solomon, SR; Zhang, X | 1 |
| Bene, MC; Blin, N; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lode, L; Loirat, M; Mahe, B; Malard, F; Mohr, C; Mohty, M; Moreau, P; Peterlin, P; Planche, L | 1 |
| Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA | 1 |
| Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A | 1 |
| Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Kangarloo, SB; Larratt, L; Russell, JA; Savoie, ML; Shafey, M; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Yue, P; Zacarias, N | 1 |
| Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
| Chen, BA; Ding, BH; Ding, JH; Li, YF; Qian, J; Yu, ZP | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N | 1 |
| Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B | 1 |
| Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Crocchiolo, R; Devillier, R; El-Cheikh, J; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Mohty, B; Oudin, C; Rey, J; Stoppa, AM; Vey, N | 1 |
| Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
| Craig, M; Cumpston, A; Evans, K; Goff, L; Hamadani, M; Kanate, AS; Leadmon, S; Rauenzahn, S; Truong, Q; Wen, S; Zhang, J | 1 |
| Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP | 1 |
| Choi, I; Jang, YJ; Jeon, M; Jung, SJ; Kang, M; Kang, YA; Kim, DY; Kim, H; Kim, HJ; Lee, JH; Lee, JL; Lee, KH; Lee, YS; Park, SY; Seol, M; Yeom, YI; Yoon, SR; Yun, SC | 1 |
| González-Ramírez, MP; Hernández-Reyes, J; Martagón-Herrera, NA; Rosales-Durón, AD; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G | 1 |
| Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O | 1 |
| Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S | 1 |
| Blin, N; Brissot, E; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lodé, L; Mahé, B; Mohty, M; Moreau, P; Peterlin, P | 1 |
| Coiteux, V; de Berranger, E; Duhamel, A; Duléry, R; Gauthier, J; Gomez, E; Langlois, C; Magro, L; Terriou, L; Yakoub-Agha, I | 1 |
| Blaise, D; Chevallier, P; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Le Gouill, S; Malard, F; Milpied, N; Mohty, M; Moreau, P; Tabrizi, R; Vigouroux, S | 1 |
| Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N | 1 |
| Champlin, RE; Eapen, M; Horowitz, MM; Lee, SJ; Logan, BR; Perales, MA; Rocha, V; Soiffer, RJ; Zhong, X | 1 |
| Chen, H; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Baron, F; Beguin, Y; De Becker, A; Emonds, MP; Graux, C; Kerre, T; Lewalle, P; Maertens, J; Ory, A; Seidel, L; Theunissen, K; Van Gelder, M; Willems, E; Zachée, P | 1 |
| Ahmed, S; Al Atrash, G; Alousi, AM; Andersson, B; Brammer, JE; Champlin, RE; Chen, J; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Nieto, Y; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saliba, RM; Shah, N; Shpall, EJ | 1 |
| Arthur, C; Fay, K; Gifford, G; Greenwood, M; Kerridge, I; Stevenson, W; Wong, K | 1 |
| Bashey, A; Brown, SL; Connor, K; Hilton, S; Holland, HK; Morris, LE; Sanacore, M; Solomon, SR; Zhang, X | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Deng, L; Guo, KY; He, YZ; Huang, YX; Lin, X; Long, H; Lu, ZG; Song, CY; Tu, SF; Wu, BY; Xu, JH | 1 |
| Bemer, MJ; Heimfeld, S; Mager, DE; McCune, JS; Sandmaier, BM; Storer, BE | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ | 1 |
| Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W | 1 |
| Du, Q; Jiang, X; Li, Q; Meng, F; Mo, W; Wei, Y; Yu, B; Zhou, M | 1 |
| Bruce, AJ; Chaudhry, HM; Hashmi, SK; Hogan, WJ; Kremers, WK; Litzow, MR; Patnaik, MS; Phillips, GL; Wolf, RC | 1 |
| Iida, H; Kato, T; Kawashima, N; Kohno, A; Kusumoto, S; Kuwatsuka, Y; Miyamura, K; Miyao, K; Mizuta, S; Morishita, Y; Murata, M; Naito, K; Nakase, K; Nishida, T; Ozawa, Y; Sao, H; Sawa, M; Taji, H; Tsurumi, H | 1 |
| Fuji, S; Fukuda, T; Hagiwara, S; Hatanaka, K; Hidaka, M; Ito, T; Kim, SW; Kurosawa, S; Nakamae, H; Ohashi, K; Takami, A; Yamaguchi, T; Yamashita, T; Yano, S | 1 |
| Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE | 1 |
| Aoki, J; Fujii, E; Ishigatsubo, Y; Kanamori, H; Matsumoto, K; Tanaka, M; Yamamoto, E; Yamamoto, W | 1 |
| Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ | 1 |
| Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X | 1 |
| Choi, ES; Im, HJ; Jang, S; Koh, KN; Kwon, SW; Lee, SW; Park, CJ; Seo, JJ; Suh, JK | 1 |
| Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Choe, HK; Gergis, U; Mayer, SA; Nagar, H; Phillips, AA; Shore, TB; Smith, MJ; van Besien, K | 1 |
| Daly, A; Geddes, M; Lam, W; Li, H; Storek, J | 1 |
| Bigley, V; Collin, M; Craddock, C; Dickinson, AM; Green, K; Jackson, G; Jardine, L; Mackinnon, S; Nagra, S; Nicolson, PLR; Pearce, K; Peggs, KS; Sellar, RS; Thomson, K | 1 |
| Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duan, Q; Duggan, P; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N | 1 |
| Fujimori, Y; Hara, H; Ikegame, K; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Ogawa, H; Okada, M; Okikawa, Y; Satake, A; Takatsuka, H; Tamaki, H | 1 |
| Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ | 1 |
| Andresen, S; Bolwell, BJ; Chan, J; Cherni, K; Copelan, E; Dean, R; Ferraro, C; Kalaycio, M; Macklis, R; Pohlman, B; Rybicki, LA; Sobecks, RM; Sweetenham, J; Theil, KS | 1 |
| Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ | 1 |
| Baron, F; Baudoux, E; Beguin, Y; Bonnet, C; Fillet, G; Frère, P; Gothot, A; Hafraoui, K; Herens, C; Seidel, L; Vanbellinghen, JF; Vanstraelen, G; Wanten, N; Willems, E | 1 |
| Ahmed, N; Bollard, CM; Brenner, MK; Carrum, G; Gottschalk, S; Heslop, HE; Krance, RA; Leung, KS; Myers, GD; Rosenblatt, H | 1 |
| Kersting, S; Verdonck, LF | 1 |
| Briones, J; Brunet, S; Delgado, J; Marco, A; Martino, R; Moreno, E; Piñana, J; Sierra, J; Sureda, A; Valcarcel, D | 1 |
| Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Amdur, RJ; Buzzeo, MP; Cable, C; Jamieson, K; Khan, S; Leather, H; Moreb, J; Reddy, V; Schold, JD; Scornik, J; Wingard, JR | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G | 1 |
| Bruno, B; Chauncey, TR; Maloney, DG; Maris, MB; Nakamae, H; Panse, J; Petersdorf, E; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Wade, JC; Woolfrey, A | 1 |
| Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ | 1 |
| Ansell, SM; Elliott, MA; Gastineau, DA; Hogan, WJ; Holtan, SG; Inwards, DJ; Johnston, PB; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ | 1 |
| Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR | 1 |
| Andersson, BS; Valdez, BC | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; El Cheikh, J; Esterni, B; Farnault, L; Faucher, C; Fürst, S; Ladaique, P; Lemarie, C; Marchetti, N; Mohty, M; Prebet, T; Stoppa, AM; Vey, N | 1 |
| Dagis, A; Forman, S; Hitt, D; Naeem, H; Qian, D; Rosenthal, J; Stein, A; Thomas, SH; Wong, J | 1 |
| Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Béliveau, C; Cohen, S; Kent, D; Kiss, T; Labbé, AC; Lachance, S; Laverdière, M; Logvinenko, T; Martel-Laferrière, V; Roy, J; Snydman, DR; Su, SH | 1 |
| Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ | 1 |
| Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; El Kourashy, S; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Zacarias, N | 1 |
| Dan, K; Mizuki, T; Nakamura, H; Nakayama, K; Tajika, K; Yamaguchi, H | 1 |
| Nagler, A; Shimoni, A | 1 |
| Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC | 1 |
| Huisman, C; Paquay, MM; Tilanus, MG; van der Straaten, HM; van Geloven, N; Verdonck, LF | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Bautista, G; Cabrera, JR; Gonzalo-Daganzo, R; Regidor, C | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR | 1 |
| Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF | 1 |
| Brychtova, Y; Doubek, M; Dvorakova, D; Horky, O; Krejci, M; Lengerova, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M | 1 |
| Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL | 1 |
| Agura, E; Bethge, W; Blume, KG; Bruno, B; Chauncey, TR; Franke, GN; Georges, GE; Hari, P; Hübel, K; Langston, A; Laport, GG; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Mielcarek, M; Niederwieser, D; Petersen, FB; Pulsipher, MA; Sahebi, F; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Vindeløv, L; Yeager, A | 1 |
| Mineishi, S | 1 |
| Anne, N; Eeva, J; Heli, U; Liisa, V; Tapani, R | 1 |
| Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR | 1 |
| Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C | 1 |
| Agrawal, S; Auer, RL; Cavenagh, JD; Davies, JK; Gribben, JG; Lister, TA; MacDougall, F; Oakervee, HE; Syndercombe-Court, D; Taussig, D | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Aker, M; Dray, L; Grisariu, S; Kedmi, M; Or, R; Resnick, IB; Shapira, MY; Stepensky, P | 1 |
| DeCook, LJ; Hogan, WJ; Holtan, SG; Huneke, T; Johnson, ND; Litzow, MR; Patnaik, MM; Porrata, LF; Thoma, M; Wiegand, RA | 1 |
| Galaup, A; Paci, A | 1 |
| Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P | 1 |
| Blaise, D; Castagna, L | 1 |
| Barba, P; Carreras, E; Fernández-Avilés, F; Garcia-Cadenas, I; López Corral, L; López-Anglada, L; Martino, R; Novelli, S; Pérez-Simón, JA; Piñana, JL; Rovira, M; Sierra, J; Valcárcel, D | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; MacKinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Ruiz de Elvira, MC; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K | 1 |
| Hansz, J | 1 |
| Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Feinstein, L; Forman, S; Georges, GE; Hegenbart, U; Little, MT; Malone, DG; Maris, M; McSweeney, PA; Niederweiser, D; Pulsipher, MA; Radich, JP; Sahebi, F; Sandmaier, BM; Shizuru, JA; Storb, R; Woolfrey, AE | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Ayash, L; Braun, T; Ferrara, JL; Hutchinson, R; Levine, JE; Ratanatharathorn, V; Reynolds, C; Silver, SM; Uberti, JP; Yanik, G | 1 |
| Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Agura, EA; Blume, KG; Chauncey, TR; Feinstein, LC; Forman, SJ; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Pulsipher, MA; Sandmaier, BM; Storb, RF; Stuart, MJ | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Amin, K; Chen, YH; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sossman, J; Stock, W; Van Besien, K; Wickrema, A; Yassine, M | 1 |
| Ogawa, H | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Lokhorst, HL; Petersen, EJ; Verdonck, LF | 1 |
| Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A | 1 |
| Amadori, S; Ballatore, G; Caravita, T; Catalano, G; Cristina Cox, M; Cudillo, L; Cupelli, L; Dentamaro, T; Fabritiis Pd, Pd; Picardi, A; Venditti, A | 1 |
| Al-Kadhimi, Z; Angelopoulou, M; Cohen, S; Falk, PM; Forman, SJ; Fung, HC; Kogut, N; Krishnan, AY; Nademanee, A; O'Donnell, MR; Parker, P; Popplewell, L; Rodriguez, R; Sahebi, F; Schriber, J; Senitzer, D; Slovak, M; Smith, D; Snyder, DS; Somlo, G; Spielberger, R; Stein, A | 1 |
| Carella, AM | 1 |
| Hillmen, P | 1 |
| Baker, JE; Baron, F; Blume, KG; Chauncey, TR; Gooley, TA; Grumet, FC; Heimfeld, S; Little, MT; Maloney, DG; Maris, MB; Oparin, D; Radich, JP; Sandmaier, BM; Storb, R; Zellmer, E | 1 |
| Avivi, I; Chakrabarti, S; Dogan, A; Goldstone, AH; Kottaridis, P; Kyriaku, C; Linch, D; Mackinnon, S; Milligan, DW | 1 |
| Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I | 1 |
| Buser, A; Gratwohl, A; Heim, D; Kostova, G; Passweg, J; Tichelli, A | 1 |
| Brecher, BA; Butrin, L; Goldberg, SL; Hsu, JS; Kobbe, K; McKiernan, P; Pecora, AL; Preti, R; Rowley, SD | 1 |
| Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M | 1 |
| Cao, TM; Grumet, FC; Johnston, LJ; Laport, GG; Lowsky, R; Negrin, RS; Sheehan, K; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM | 1 |
| Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N | 1 |
| Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B | 1 |
| Brenner, MK; Carrum, G; Heslop, HE; Krance, RA; Lamba, R; May, R; Popat, U | 1 |
| Hara, S; Hayashi, S; Kamimura, T; Ogata, K; Suzumiya, J; Takamatsu, Y; Tamura, K; Yamauchi, K | 1 |
| Mielcarek, M; Storb, R | 1 |
| Barrett, AJ; Childs, R; Kurlander, R; Leitman, SF; Montero, A; Read, EJ; Savani, BN; Solomon, SR | 1 |
| Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D | 1 |
| Austin, H; Balow, JE; Barrett, J; Childs, R; Geller, N; Igarashi, T; Lundqvist, A; Sabnis, S; Srinivasan, R; Takahashi, Y; Tisdale, J | 1 |
| Chen, L; Ng, AP; Prince, HM; Seymour, JF; Slavin, M; Thursky, K; Worth, L | 1 |
| Cassoni, A; Cooper, N; Delgado, J; Duarte, R; Jarmulowicz, M; Kottaridis, P; Mackinnon, S; Peggs, K; Thomson, K | 1 |
| Champlin, RC; Chan, KW; Choroszy, M; Ha, CS; Madden, R; Mahajan, A; Mullen, CA; Petropoulos, D; Worth, LL | 1 |
| Barón, A; Bearman, SI; Hawkins, T; Jones, RB; McSweeney, PA; Nieto, Y; Patton, N; Rabinovitch, R; Shpall, EJ; Spearing, R; Zeng, C | 1 |
| Fujimori, Y; Hara, H; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Nomura, K; Ogawa, H; Okada, M; Takatsuka, H; Toda, A; Wakae, T | 1 |
| Inamoto, Y; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Oba, T; Tokunaga, M; Tsujimura, A | 1 |
| Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Kliem, C; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Pulsipher, M; Sandmaier, BM; Shizuru, JA; Storb, R; Storer, BE; Wade, J | 1 |
| Inamoto, Y; Kasai, M; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Murata, M; Naoe, T; Oba, T; Terakura, S; Tokunaga, M; Tsujimura, A | 1 |
| Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM | 1 |
| Coleman, M; Feldman, EJ; Harpel, J; Leonard, JP; Roboz, GJ; Schuster, MW; Shore, T; Silver, RT | 1 |
| Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ | 1 |
| Taniguchi, S | 1 |
| Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Montillo, M; Ricci, F; Tedeschi, A | 1 |
| Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E | 1 |
| Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D | 1 |
| Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ | 1 |
| Brown, C; Chaudhry, A; Larratt, L; Morris, D; Quinlan, D; Russell, JA; Stewart, D; Turner, AR | 1 |
| Bauters, F; Berthon, C; Boulanger, F; Cracco, P; Darré, S; Jouet, JP; Micol, JB; Terriou, L; Tricot, S; Yakoub-Agha, I | 1 |
| Antolak, J; Chan, KW; Ha, CS; Kornguth, DG; Mahajan, A; Woo, S | 1 |
| Choi, Y; Keam, B; Kim, BK; Kim, I; Koo, NH; Lee, KH; Park, S; Yoo, KY; Yoon, SS | 1 |
| Barker, JN; Blazar, BR; Brunstein, CG; DeFor, TE; McGlave, PB; Miller, JS; Wagner, JE; Weisdorf, DJ | 1 |
| Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T | 1 |
| Chen, CS; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Lee, YM; Lim, S; Linn, YC; Liu, TC; Loh, YS; Mow, BM; Ng, HJ; Ng, HY; Tai, BC; Tan, B; Tan, DC; Tan, KW; Tan, LK; Tan, PH | 1 |
| Allione, B; Bacigalupo, A; Baldi, I; Bruno, B; Busca, A; Falda, M; Locatelli, F; Mordini, N; Morello, E; Narni, F; Rambaldi, A; Santarone, S | 1 |
| Demidova, IA; Kut'ina, RM; Misiurin, AV; Ol'shanskaia, IuV; Parovichnikova, EN; Poreshina, LP; Savchenko, VG; Shpakova, AP | 1 |
| Bamberg, M; Belka, C; Bethge, W; Faul, C; Handgretinger, R; Heinzelmann, F; Lang, PJ; Ottinger, H | 1 |
| Andersson, BS; Bahlis, NJ; Brown, C; Chaudhry, MA; Geddes, M; Kangarloo, SB; Naveed, F; Quinlan, D; Russell, JA; Savoie, ML; Stewart, D; Storek, J | 1 |
| Attal, M; Blaise, D; Boiron, JM; Bordigoni, P; Bourhis, JH; Chir, Z; Deconinck, E; Esperou, H; Le, QH; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Nicolini, F; Prébet, T; Renaud, M; Rio, B; Yakoub-Agha, I | 1 |
| Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A | 1 |
| Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
| Curbo, S; Karlsson, A | 1 |
| Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Chen, AR; Flowers, M; Fuchs, EJ; Gooley, TA; Harrington, E; Huff, CA; Jones, RJ; Kaup, M; Leffell, MS; Luznik, L; Matsui, W; O'Donnell, PV; Piantadosi, S; Powell, JD; Sandmaier, BM; Storb, RF; Symons, HJ; Warnock, S; Zahurak, M | 1 |
| Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Dimopoulos, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Lerner, S; McLaughlin, P; O'Brien, S; Plunkett, W | 1 |
| Adkins, JC; Markham, A; Peters, DH | 1 |
| Hájek, R; Krahulcová, E; Mayer, J; Penka, M; Vásová, I | 1 |
| Bolam, S; Hamblin, TJ; Myint, H; Orchard, J; Oscier, DG | 1 |
| Champlin, R; Giralt, S; Khouri, I | 1 |
| Grigg, A; Roberts, A; Seymour, JF; Szer, J | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Harousseau, JL; Mahé, B; Milpied, N; Morin, O; Rapp, MJ; Vigouroux, S | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Antin, JH; Duffy, KM; Kathakali, A; Laport, G; Leonard, DG; Luger, SM; McDaid, K; Orloff, G; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, D | 1 |
| Blume, KG; Chauncey, T; Forman, S; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Sandmaier, BM; Shizuru, J; Storb, R; Woolfrey, A | 1 |
| Derigs, HG; Fischer, T; Huber, C; Kolbe, K; Kreiter, S; Schneider, PM; Schuler, M; Ullmann, AJ; Winkelmann, N | 1 |
| Akerstein, A; Engelhard, D; Gelfand, Y; Morecki, S; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G | 1 |
| Johnson, SA | 1 |
| Chizuka, A; Iijima, K; Iizuka, A; Kamijo, K; Kanai, S; Kanda, Y; Kawano, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Ueda, K; Wakasugi, H; Yakushijin, K | 1 |
| Amin, K; Chen, YH; Devine, H; Devine, SM; Huml, M; Jessop, E; Maningo, M; Peace, D; Sanborn, R; Stock, W; Thomason, D; van Besien, K; Wickrema, A; Yassine, M | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Pagnucco, G; Varettoni, M | 1 |
| Abreu-Díaz, G; Bravo, G; Gómez-Almaguer, D; Jaime-Pérez, JC; López-Martínez, B; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Gabrilove, JL | 1 |
| Bensinger, WI; Gooley, T; Maloney, DG; Sandmaier, BM; Storb, R; Weissinger, F | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Branson, K; Chakrabarti, S; Chakraverty, R; Chopra, R; Craddock, C; Geary, J; Goldstone, AH; Hale, G; Hunter, A; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, DW; Parker, A; Peggs, K; Thuraisundaram, D; Verfuerth, S; Waldmann, H; Williams, CD; Yong, K | 1 |
| Beltrami, G; Carella, AM; Cavaliere, M; Corsetti, MT; Lerma, E | 1 |
| Goldschmidt, H; Görner, M; Ho, AD; Kordelas, L; Luft, T; Moos, M; Pfeiffer, S; Punzel, M; Thalheimer, M; Ustaoglu, F; Weber-Nordt, R | 1 |
21 review(s) available for fludarabine and Hematologic Neoplasms
| Article | Year |
|---|---|
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Methotrexate; Mouth Mucosa; Myeloablative Agonists; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine | 2010 |
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Myeloablative Agonists; Ovarian Neoplasms; Vidarabine; Whole-Body Irradiation | 2013 |
Do different conditioning regimens really make a difference?
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
[Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Host vs Graft Reaction; Humans; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
[Mini-transplantation from HLA-mismatched donors].
Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Treatment Outcome; Vidarabine | 2004 |
Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.
Topics: Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Time Factors; Transplantation Conditioning; Vidarabine | 2005 |
[Reduced-intensity cord blood transplantation for adult hematological diseases].
Topics: Adult; Age Factors; Antigens, CD34; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2006 |
Role of fludarabine in hematological malignancies.
Topics: Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Prodrugs; Vidarabine | 2006 |
Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Topics: Arabinonucleosides; Clinical Trials as Topic; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Leukemia-Lymphoma, Adult T-Cell; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine | 2006 |
Pharmacology of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Clinical experience with fludarabine in hemato-oncology.
Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Vidarabine | 1996 |
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Drug Tolerance; Hematologic Neoplasms; Humans; Vidarabine | 1997 |
[A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Vidarabine | 1997 |
Non myeloablative "mini transplants".
Topics: Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Vidarabine | 1999 |
Non-myeloablative hematopoietic stem cell transplantation.
Topics: Animals; Bone Marrow; Chimera; Cyclosporine; Dogs; Drug Administration Schedule; Graft Rejection; Graft Survival; Graft vs Host Reaction; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Models, Animal; Mycophenolic Acid; Safety; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Apoptosis; Cytokines; Fibroblast Growth Factor 2; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.
Topics: Breast Neoplasms; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2002 |
88 trial(s) available for fludarabine and Hematologic Neoplasms
| Article | Year |
|---|---|
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Myelopoiesis; Myeloproliferative Disorders; Neoplasms, Second Primary; Sulfonamides; Vidarabine | 2022 |
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine | 2022 |
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neoplasm Recurrence, Local | 2023 |
Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine.
Topics: Adult; Basiliximab; Cyclophosphamide; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Vidarabine | 2020 |
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
Topics: Aged; Allografts; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Neutrophils; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Survival Rate; Vidarabine | 2018 |
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Retrospective Studies; Survival Rate; Vidarabine | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
Topics: Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Enzyme Inhibitors; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recovery of Function; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2019 |
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Topics: Acute Disease; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2019 |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Oral versus intravenous fludarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Maltose; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.
Topics: Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Rabbits; Survival Rate; Transplantation Conditioning; Vidarabine | 2015 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Risk; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Myeloablative Agonists; Risk Assessment; Siblings; Survival Analysis; Survival Rate; Vidarabine | 2008 |
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Cell Count; Communicable Diseases; Dendritic Cells; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Lymphocytes; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female; Glutathione Transferase; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Polymorphism, Genetic; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.
Topics: Adult; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Double-Blind Method; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Transplantation Conditioning; Vidarabine; Zinc Sulfate | 2012 |
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Administration Schedule; Drug Dosage Calculations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Tissue Donors; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mycophenolic Acid; Radiotherapy, Adjuvant; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Survival; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Histocompatibility; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Topics: Adult; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Opportunistic Infections; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mycophenolic Acid; Opportunistic Infections; Premedication; Prospective Studies; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Nervous System Diseases; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Diseases | 2004 |
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
Topics: Adult; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Analysis; Thrombocytopenia; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2004 |
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
Topics: Adult; Age Distribution; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Combined Modality Therapy; Female; Glycoproteins; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Leukocyte Common Antigens; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Mouth Mucosa; Stomatitis; Survival Rate; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Topics: Adolescent; Adult; Aged; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine | 2006 |
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Melphalan; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Interactions; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Matched-Pair Analysis; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; International Cooperation; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Topics: Aged; Agranulocytosis; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Reoperation; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Monitoring; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Topics: Adult; Aged; Blood Component Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Filgrastim; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Care; Postoperative Complications; Recombinant Proteins; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Chimera; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2001 |
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Lineage; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; Transplantation Chimera; Vidarabine | 2001 |
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Erythrocyte Transfusion; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Nuclear Family; Platelet Transfusion; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2001 |
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Melphalan; Middle Aged; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
113 other study(ies) available for fludarabine and Hematologic Neoplasms
| Article | Year |
|---|---|
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Randomized Controlled Trials as Topic; Research Design; Vidarabine | 2020 |
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Propensity Score; Transplantation Conditioning; Vidarabine | 2021 |
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults.
Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Neutrophils; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine | 2021 |
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Iran; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Risk Factors; Transplantation Conditioning; Vidarabine | 2017 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Visual loss secondary to fludarabine toxicity: optical coherence tomography findings in two patients.
Topics: Antineoplastic Agents; Follow-Up Studies; Hematologic Neoplasms; Humans; Prognosis; Retina; Tomography, Optical Coherence; Vidarabine; Vision, Low; Visual Acuity; Visual Field Tests; Visual Fields | 2019 |
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
Topics: Adult; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Homologous; Vidarabine | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lung Diseases; Lymphocytes; Male; Middle Aged; Mucositis; Outcome Assessment, Health Care; Proportional Hazards Models; Quality of Life; Recovery of Function; Retrospective Studies; Surveys and Questionnaires; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lung; Male; Myeloablative Agonists; Roseolovirus Infections; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Patient Readmission; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine | 2015 |
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Outcome Assessment, Health Care; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Analysis; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2015 |
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.
Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Comorbidity; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Vidarabine | 2015 |
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Infant; Lymphocyte Depletion; Male; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Radiation Dosage; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2017 |
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.
Topics: Adult; Aged; Alemtuzumab; Allografts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cord Blood Stem Cell Transplantation; Cytarabine; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Kinetics; Male; Middle Aged; Risk Assessment; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2008 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Living Donors; Lymphocyte Transfusion; Male; Metabolic Diseases; Prospective Studies; Retrospective Studies; Severe Combined Immunodeficiency; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2008 |
Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Cyclosporine; Disease-Free Survival; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Mycophenolic Acid; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Clinical Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine | 2010 |
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2010 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.
Topics: Antiviral Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Neuralgia, Postherpetic; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation | 2011 |
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine | 2010 |
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Maximum Tolerated Dose; Monitoring, Physiologic; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nod2 Signaling Adaptor Protein; Polymorphism, Single Nucleotide; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
Topics: Adolescent; Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Radiation Dosage; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.
Topics: Antineoplastic Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Myeloablative Agonists; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocytes; Male; Melphalan; Middle Aged; Monocytes; Prognosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Blood Platelets; Female; Ferritins; Follow-Up Studies; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
[Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2004 |
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Chimera; Disease Progression; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
Topics: Adult; Aged; Antigens, CD; CD8-Positive T-Lymphocytes; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Cell Fractionation; Cohort Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.
Topics: Adolescent; Adult; Child; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Topics: Acyclovir; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Diphtheria Toxin; DNA, Viral; Doxorubicin; Female; Fever; Follow-Up Studies; Ganciclovir; Hematologic Neoplasms; Humans; Interleukin-2; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Transplantation, Autologous; Valacyclovir; Valine; Vidarabine; Vincristine; Viremia; Virus Activation | 2005 |
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Topics: Adult; Bone Marrow; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
[Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
Topics: Adult; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; DNA (Cytosine-5-)-Methyltransferases; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
Topics: Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Melphalan; Myeloablative Agonists; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloablative Agonists; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphatic Irradiation; Middle Aged; Muromonab-CD3; Peripheral Blood Stem Cell Transplantation; Pneumonia; Retreatment; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; France; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Vidarabine | 1998 |
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Vidarabine | 1999 |
[Cryptococcus neoformans infection in hematologic malignancies].
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Cryptococcus neoformans; Female; France; Hematologic Neoplasms; Humans; Immunity, Cellular; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Vidarabine | 2000 |
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Topics: Adult; Chediak-Higashi Syndrome; Cyclosporine; Fatal Outcome; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; T-Lymphocytes; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Failure; Vidarabine; Whole-Body Irradiation | 2001 |
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Cell Culture Techniques; Child; Child, Preschool; Cytotoxicity, Immunologic; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Infections; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens.
Topics: Adolescent; Adult; Antigens, CD34; Blood Cell Count; Child; Child, Preschool; Female; Graft Survival; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
Topics: Adult; Cohort Studies; Disease Progression; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Retrospective Studies; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |